Andrew Obenshain is the Chief Executive Officer of bluebird bio, a biotechnology company that develops gene therapies for severe genetic disorders.
Andrew Obenshain is the Chief Executive Officer of bluebird bio, a biotechnology company that develops gene therapies for severe genetic disorders. He previously served as president of the company's genetic diseases business. Obenshain leads bluebird bio's efforts to advance therapies for rare diseases.
Full founder directory · Investor directory · Company funding database · Fundraising library